

# Toxo IgG Avidity

IgG antibody avidity to *Toxoplasma gondii*

cobas®

REF		SYSTEM
05802571 190	100; equals to 50 Toxo IgG avidity determinations	Elecsys 2010 MODULAR ANALYTICS E170 <b>cobas e 411</b> <b>cobas e 601</b> <b>cobas e 602</b>

## English

### Intended use

Immunoassay for the in vitro qualitative determination of the avidity of IgG antibodies to *Toxoplasma gondii* in human serum and plasma.

The electrochemiluminescence immunoassay "ECLIA" is intended for use on Elecsys and **cobas e** immunoassay analyzers.

### Summary

Toxoplasmosis is a common infection caused by the protozoan parasite *Toxoplasma gondii*.

The infection is mainly acquired by ingesting food or water contaminated by cat feces (and containing mature *T. gondii* oocysts), or eating undercooked meat from infected animals. Primary, acute infection, which is mostly mild or even asymptomatic in healthy individuals, is followed by a latent infection that usually persists for life. However, reactivation of a latent toxoplasma infection as a result of immunosuppression (e.g. in organ transplant recipients, AIDS patients) is frequently associated with meningoencephalitis. Primary maternal toxoplasma infection occurring during pregnancy can result in severe damage to the fetus as the parasite can be transmitted across the placenta. The majority of infants with congenital infection do not present clinical symptoms at birth but may develop severe sequelae later in life, such as mental and psychomotor retardation, chorioretinitis, and hearing loss. The fetal infection rate increases with gestational age, but the risk of severe clinical manifestations is higher when maternal infection occurs early in the pregnancy. Early intervention with drug therapy in cases of acute infection during pregnancy can prevent congenital damage or ameliorate the severity of clinical manifestations.<sup>1,2,3,4,5,6</sup> In the absence of acute clinical symptoms the diagnosis of toxoplasma infection is based on serologic marker testing, namely IgG and IgM directed against *T. gondii*. IgM is considered to be an acute-phase marker, but positive IgM results can also be observed due to polyclonal stimulation or detection of residual or persistent IgM months or even years after the primary infection. Due to this fact, a complementary technique is needed to help refine the date of infection and thus enable appropriate counseling and management of pregnancy. Toxoplasma IgG avidity assays are currently the most reliable method to rule out infection occurring within the last 4 months. The Elecsys Toxoplasma IgG avidity assay measures the functional binding affinity of *T. gondii* IgG in response to infection. The antibodies produced during the non-primary response or in the remote phase of infection have a higher antigen avidity than antibodies produced during the primary response. No clinical interpretation can be deduced from a low or gray-zone avidity result. Avidity testing should be performed early in gestation; a high avidity result later than the fourth month of gestation cannot rule out a primary infection earlier in gestation when low avidity *T. gondii* IgG may have been present. The detection of high IgG avidity during the first trimester of pregnancy can be considered a good indicator of past infection.<sup>7,8</sup>

### Test principle

The test principle is based on two, parallel measurements with the Elecsys Toxo IgG Avidity assay.

One aliquot of the sample is diluted with Diluent Universal (DilUni) and this mixture serves as a reference.

A second aliquot of the sample is diluted with Diluent Toxo Avidity (DilToxoAv). During incubation with DilToxoAv, IgG antibodies directed against *Toxoplasma gondii* are bound to *T. gondii*-specific recombinant antigen present in the DilToxoAv diluent.

Both dilution steps have to be performed manually.

The Elecsys Toxo IgG Avidity assay uses the sandwich principle.

Total duration of the assay on the analyzer is 18 minutes for both the reference and DilToxoAv treated samples.

- 1st incubation: 10 µL of sample, a biotinylated recombinant *T. gondii*-specific antigen, and a *T. gondii*-specific recombinant antigen labeled with a ruthenium complex<sup>a)</sup> form a sandwich complex.
- 2nd incubation: After addition of streptavidin-coated microparticles, the complex becomes bound to the solid phase via interaction of biotin and streptavidin.
- The reaction mixture is aspirated into the measuring cell where the microparticles are magnetically captured onto the surface of the electrode. Unbound substances are then removed with ProCell/ProCell M. Application of a voltage to the electrode then induces chemiluminescent emission which is measured by a photomultiplier.
- Results are determined via a calibration curve which is instrument-specifically generated by 2-point calibration and a master curve provided via the reagent barcode.
- The avidity (Avi%) is assessed by determining the ratio between the result (IU/mL) obtained from the aliquot diluted with Diluent Toxo Avidity and the result from the reference aliquot.

a) Tris(2,2'-bipyridyl)ruthenium(II)-complex (Ru(bpy)<sub>3</sub><sup>2+</sup>)

### Reagents - working solutions

The reagent rackpack (M, R1, R2) is labeled as TOXO-AV.

- M Streptavidin-coated microparticles (transparent cap), 1 bottle, 6.5 mL:  
Streptavidin-coated microparticles 0.72 mg/mL; preservative.
- R1 Toxoplasma-Ag-biotin (gray cap), 1 bottle, 9 mL:  
Biotinylated *T. gondii*-specific antigen (recombinant, *E. coli*), > 400 µg/L, TRIS buffer 50 mmol/L, pH 7.5; preservative.
- R2 Toxoplasma-Ag-Ru(bpy)<sub>3</sub><sup>2+</sup> (black cap), 1 bottle, 9 mL:  
*T. gondii*-specific antigen (recombinant, *E. coli*) labeled with ruthenium complex > 400 µg/L; TRIS buffer 50 mmol/L, pH 7.5; preservative.
- TOXO-AV Cal1 Negative calibrator 1 (white cap), 2 bottles of 1.0 mL each:  
Human serum, non-reactive for anti-Toxoplasma IgG; buffer; preservative.
- TOXO-AV Cal2 Positive calibrator 2 (black cap), 2 bottles of 1.0 mL each:  
Human serum, reactive for anti-Toxoplasma IgG, approximately 100 IU/mL; buffer; preservative.
- DilToxoAv Avidity Diluent (white cap) for manual dilutions, 1 bottle, 12 mL:  
*T. gondii*-specific antigen (recombinant, *E. coli*) in protein matrix, buffer, pH 7.4; preservative.

### Precautions and warnings

For in vitro diagnostic use.

Exercise the normal precautions required for handling all laboratory reagents.

Disposal of all waste material should be in accordance with local guidelines. Safety data sheet available for professional user on request.

All human material should be considered potentially infectious.

Both calibrators (TOXO-AV Cal1, TOXO-AV Cal2) have been prepared exclusively from the blood of donors tested individually and shown to be free from HBsAg and antibodies to HCV and HIV.

# Toxo IgG Avidity

## IgG antibody avidity to *Toxoplasma gondii*

The serum containing anti-Toxoplasma IgG (TOXO-AV Cal2) was sterile filtrated.

The testing methods applied were FDA-approved or cleared in compliance with the European Directive 98/79/EC, Annex II, List A.

However, as no testing method can rule out the potential risk of infection with absolute certainty, the material should be handled with the same level of care as a patient specimen. In the event of exposure, the directives of the responsible health authorities should be followed.<sup>9,10</sup>

Avoid foam formation in all reagents and sample types (specimens, calibrators and controls).

### Reagent handling

The reagents in the kit are ready for use and are supplied in bottles compatible with the system (except for DilToxoAv).

Elecsys 2010 and **cobas e** 411 analyzers: The calibrators should only be left on the analyzers during calibration at 20-25 °C. After use, close the bottles as soon as possible and store upright at 2-8 °C.

Due to possible evaporation effects, not more than 5 calibration procedures per bottle set should be performed.

MODULAR ANALYTICS E170, **cobas e** 601 and **cobas e** 602 analyzers: Unless the entire volume is necessary for calibration on the analyzers, transfer aliquots of the ready-for-use calibrators into empty snap-cap bottles (CalSet Vials). Attach the supplied labels to these additional bottles. Store the aliquots at 2-8 °C for later use.

Perform **only one** calibration procedure per aliquot.

All information required for correct operation is read in from the respective reagent barcodes.

*Please note:* Both the vial labels, and the additional labels (if available) contain 2 different barcodes. The barcode between the yellow markers is for **cobas** 8000 systems only. If using a **cobas** 8000 system, please turn the vial cap 180° into the correct position so the barcode can be read by the system. Place the vial on the instrument as usual.

### Storage and stability

Store at 2-8 °C.

Do not freeze.

Store the Elecsys reagent kit **upright** in order to ensure complete availability of the microparticles during automatic mixing prior to use.

Stability of the reagent rackpack and DilToxoAv	
unopened at 2-8 °C	up to the stated expiration date
M, R1, R2, DilToxoAv after opening at 2-8 °C	12 weeks
M, R1, R2 on the analyzers DilToxoAv on bench	2 weeks or 12 weeks if stored alternately in the refrigerator and on the analyzers/on bench (up to 84 hours)

Stability of the calibrators	
unopened at 2-8 °C	up to the stated expiration date
after opening at 2-8 °C	8 weeks
on Elecsys 2010 and <b>cobas e</b> 411 at 20-25 °C	up to 5 hours
on MODULAR ANALYTICS E170, <b>cobas e</b> 601 and <b>cobas e</b> 602 at 20-25 °C	use only once

Store calibrators **upright** in order to prevent the calibrator solution from adhering to the snap-cap.

### Specimen collection and preparation

Only the specimens listed below were tested in a sufficient number and found acceptable.

Serum collected using standard sampling tubes or tubes containing separating gel.

Li-heparin, K<sub>2</sub>-EDTA, K<sub>3</sub>-EDTA and Na-citrate plasma.

Criterion: Mean recovery of positive samples within 80-120 % of serum value.

Stable for 3 weeks at 2-8 °C, 3 days at 25 °C, 3 months at -20 °C. The samples may be frozen 6 times.

The sample types listed were tested with a selection of sample collection tubes that were commercially available at the time of testing, i.e. not all available tubes of all manufacturers were tested. Sample collection systems from various manufacturers may contain differing materials which could affect the test results in some cases. When processing samples in primary tubes (sample collection systems), follow the instructions of the tube manufacturer.

Specimens should not be altered subsequently with additives (biocides, anti-oxidants or substances possibly changing the pH of the sample) in order to avoid erroneous findings. Pooled samples and other artificial material may have different effects on different assays and thus may lead to discrepant findings.

Centrifuge samples containing precipitates, and frozen samples before performing the assay. Lyophilized samples and heat-inactivated samples can be used.

Ensure the samples, calibrators and controls are at 20-25 °C prior to measurement.

Due to possible evaporation effects, samples and calibrators on the analyzers should be analyzed/measured within 1 hour after manual processing (avidity sample handling).

### Materials provided

See "Reagents – working solutions" section for reagents.

### Materials required (but not provided)

- [REF](#) 10394246001, 20 x 250 sample cups, needed for the manual dilution step
- [REF](#) 05802580190, PreciControl Toxo IgG Avidity, 3 x 1 mL each of PreciControl Toxo IgG Avidity 1 and 2
- [REF](#) 04618823190, PreciControl Toxo IgG, 8 x 1 mL each of PreciControl Toxo IgG 1 and 2
- [REF](#) 11732277122, Diluent Universal, 2 x 16 mL sample diluent or [REF](#) 03183971122, Diluent Universal, 2 x 36 mL sample diluent
- [REF](#) 11776576322, CalSet Vials, 2 x 56 empty snap-cap bottles
- General laboratory equipment
- Elecsys 2010, MODULAR ANALYTICS E170 or **cobas e** analyzer

Accessories for Elecsys 2010 and **cobas e** 411 analyzers:

- [REF](#) 11662988122, ProCell, 6 x 380 mL system buffer
- [REF](#) 11662970122, CleanCell, 6 x 380 mL measuring cell cleaning solution
- [REF](#) 11930346122, Elecsys SysWash, 1 x 500 mL washwater additive
- [REF](#) 11933159001, Adapter for SysClean
- [REF](#) 11706802001, Elecsys 2010 AssayCup, 60 x 60 reaction vessels
- [REF](#) 11706799001, Elecsys 2010 AssayTip, 30 x 120 pipette tips

Accessories for MODULAR ANALYTICS E170, **cobas e** 601 and **cobas e** 602 analyzers:

- [REF](#) 04880340190, ProCell M, 2 x 2 L system buffer
- [REF](#) 04880293190, CleanCell M, 2 x 2 L measuring cell cleaning solution
- [REF](#) 03023141001, PC/CC-Cups, 12 cups to prewarm ProCell M and CleanCell M before use
- [REF](#) 03005712190, ProbeWash M, 12 x 70 mL cleaning solution for run finalization and rinsing during reagent change
- [REF](#) 12102137001, AssayTip/AssayCup Combimagazine M, 48 magazines x 84 reaction vessels or pipette tips, waste bags
- [REF](#) 03023150001, WasteLiner, waste bags
- [REF](#) 03027651001, SysClean Adapter M

Accessories for all analyzers:

- [REF](#) 11298500316, ISE Cleaning Solution/Elecsys SysClean, 5 x 100 mL system cleaning solution

# Toxo IgG Avidity

IgG antibody avidity to *Toxoplasma gondii*

cobas®

## Assay

For optimum performance of the assay follow the directions given in this document for the analyzer concerned. Refer to the appropriate operator's manual for analyzer-specific assay instructions.

Resuspension of the microparticles takes place automatically prior to use. Read in the test-specific parameters via the reagent barcode. If in exceptional cases the barcode cannot be read, enter the 15-digit sequence of numbers.

Bring the cooled reagents to approximately 20 °C and place on the reagent disk (20 °C) of the analyzer. Avoid foam formation. The system automatically regulates the temperature of the reagents and the opening/closing of the bottles.

Place the calibrators in the sample zone.

All the information necessary for calibrating the assay is automatically read into the analyzer.

After calibration has been performed, store the calibrators at 2-8 °C or discard (MODULAR ANALYTICS E170, **cobas e 601** and **cobas e 602** analyzers).

Handling of specimen for the Elecsys Toxo IgG Avidity assay:

Sample concentration needs to be defined with the Toxo IgG assay (REF 04618815190) prior to avidity measurement.

Samples found to be reactive using the Elecsys Toxo IgG assay with a concentration between 6-500 IU/mL are split into two aliquots.

If a patient sample is reactive using the Elecsys Toxo IgG assay and has a concentration > 500 IU/mL, the sample must be pre-diluted manually with Diluent Universal according to the following table **before** being split into two aliquots.

Value in Elecsys Toxo IgG assay (IU/mL)	Pre-dilution steps
≥ 6 to ≤ 500 IU/mL	<b>no</b> pre-dilution required
> 500 to < 1500 IU/mL	1:20
≥ 1500 IU/mL to < 4000 IU/mL	1:50
≥ 4000 IU/mL	1:100

Dilute one aliquot of the sample 1:2 with Diluent Universal (1 Vol. sample + 1 Vol. DilUni) and mix the diluted aliquot gently by pipetting the mixture up and down once. Dilute the second aliquot of the sample 1:2 with Diluent Toxo Avidity (1 Vol. sample + 1 Vol. DiIToxoAv) and mix as described above. Allow both aliquots to stand for at least 10 minutes at ambient temperature (20-25 °C) before placing in the analyzer. Complete all determinations on the analyzer within 1 hour of preparing the dilutions.

Measure both aliquots with the Elecsys Toxo IgG Avidity assay. The operator must ensure that the measurements are performed consecutively with the same reagent lot, the same calibration and on the same analyzer.

## Calibration

Traceability: The IU/mL has been standardized against the 3rd International Standard for anti-Toxoplasma serum (TOXM) from NIBSC, UK.

Every Elecsys Toxo IgG Avidity reagent set has a barcoded label containing specific information for calibration of the particular reagent lot. The predefined master curve is adapted to the analyzer using TOXO-AV Cal1 and TOXO-AV Cal2.

**Calibration frequency:** Calibration must be performed once per reagent lot using TOXO-AV Cal1, TOXO-AV Cal2 and fresh reagent (i.e. not more than 24 hours since the reagent kit was registered on the analyzer).

Renewed calibration is recommended as follows:

- after 1 month (28 days) when using the same reagent lot
- after 7 days (when using the same reagent kit on the analyzer)
- as required: e.g. quality control findings with PreciControl Toxo IgG Avidity outside the defined limits
- more frequently when this is required by pertinent regulations

## Quality control

For quality control, use PreciControl Toxo IgG for verification of calibration and PreciControl Toxo IgG Avidity for verification of correctly performed dilution steps and of functionality of the Diluent Toxo Avidity (DiIToxoAv).

Please note: PreciControl Toxo IgG Avidity is not barcode-labeled and requires manual preparation. These controls should be prepared in the same way as the specimen samples. For the recommended procedure please refer to the "Assay" section of this document.

- Verification of calibration using PreciControl Toxo IgG:

The target values and ranges (IU/mL) of the PreciControl Toxo IgG were determined and evaluated by Roche. They were obtained using the Elecsys Toxo IgG Avidity assay reagents and analyzers available at the time of testing. The control values obtained during testing must be within the control ranges (IU/mL) stated in the value sheet. The exact lot-specific target values and ranges are printed on the enclosed (or electronically available) value sheet.

- Verification of correctly performed 1:2 dilution using PreciControl Toxo IgG Avidity:

The target values and ranges (IU/mL) of the PreciControl Toxo IgG Avidity diluted 1:2 with Diluent Universal were determined and evaluated by Roche. They were obtained using the Elecsys Toxo IgG Avidity assay reagents and analyzers available at the time of testing. The control values obtained during testing must be within the control ranges (IU/mL) stated in the value sheet. The exact lot-specific target values and ranges are printed on the enclosed (or electronically available) value sheet.

- Verification of functionality of the Diluent Toxo Avidity (DiIToxoAv) using PreciControl Toxo IgG Avidity:

The avidity (Avi%) is calculated from the reference measurement and the DiIToxoAv-treated measurement as per the "Calculation" section of this document. The target range for the manually calculated avidity result (Avi%) of PreciControl Toxo IgG Avidity 1 is < 70 Avi%, while the respective range for PreciControl Toxo IgG Avidity 2 is ≥ 80 Avi%.

It is recommended to run PreciControl Toxo IgG 1 and 2 as well as PreciControl Toxo IgG Avidity 1 and 2 at the beginning of each working day and after every calibration.

Each laboratory should establish corrective measures to be taken if values fall outside the defined limits.

If necessary, repeat the measurement of the samples concerned.

Follow the applicable government regulations and local guidelines for quality control.

## Calculation

The analyzer automatically calculates the analyte concentration of each sample in IU/mL for both measurements (reference measurement and DiIToxoAv-treated measurement).

To calculate the avidity (Avi%) please use the formula given below.

$$\text{Avi}(\%) = 100 - \frac{\text{IU/mL of aliquot treated with DiIToxoAv}}{\text{IU/mL of aliquot treated with DilUni}} \times 100$$

Please note:

- If the concentration of the sample diluted with DilUni is < 3 IU/mL (indeterminate result) the avidity calculation cannot be performed.
- If the concentration of the sample diluted with DiIToxoAv is < 0.130 IU/mL (< lower detection limit) the avidity calculation cannot be performed.

## Interpretation of the results

Results obtained with the Elecsys Toxo IgG Avidity assay are interpreted as follows:

Avidity (Avi%)	Interpretation
< 70	low avidity
70-79	gray-zone
≥ 80	high avidity

**No clinical interpretation can be deduced from a low or gray-zone result.**

The recommendation in these cases is to take a follow-up sample within an appropriate period of time (e.g. 2-4 weeks) and repeat testing. Elecsys Toxo IgG Avidity results should be used in conjunction with the patient's

# Toxo IgG Avidity

IgG antibody avidity to *Toxoplasma gondii*

cobas®

medical history, clinical symptoms, and other laboratory tests, e.g. Toxo-specific IgG and IgM results. If a Toxo IgG avidity result is discordant with the patient's medical history, clinical symptoms and other laboratory tests, e.g. Toxo-specific IgG and IgM results, further tests should be performed to verify the result and testing of a follow-up sample is recommended. The Toxo IgG avidity results in a given specimen, as determined by assays from different manufacturers, can vary due to differences in assay methods and reagents used. Therefore, the results reported by the laboratory to the physician should include the statement: "The following results were obtained using the Elecsys Toxo IgG Avidity assay. Results from assays provided by other manufacturers cannot be used interchangeably." In rare cases a value of 0 % avidity or negative percentage avidity might be observed; these results are classified as low avidity.

## Limitations - interference

The results in HIV patients, in patients undergoing immunosuppressive therapy, or in patients with other disorders leading to immune suppression, should be interpreted with caution.

Specimens from neonates, cord blood, pre-transplant patients or body fluids other than serum and plasma, such as urine, saliva or amniotic fluid have not been tested.

The assay is unaffected by icterus (bilirubin < 684 µmol/L or < 40 mg/dL), hemolysis (Hb < 1.24 mmol/L or < 2 g/dL), lipemia (Intralipid < 2000 mg/dL) and biotin (< 246 nmol/L or < 60 ng/mL).

Criterion: Mean recovery of positive samples within ± 20 % of serum value.

Samples should not be taken from patients receiving therapy with high biotin doses (i.e. > 5 mg/day) until at least 8 hours following the last biotin administration.

No interference was observed from rheumatoid factors up to a concentration of 6210 IU/mL.

Among a panel of 30 positive samples within the measuring range (0.13-650 IU/mL) no high-dose hook effect was observed (no increasing signals upon dilution).

In vitro tests were performed on 18 commonly used pharmaceuticals and in addition on spiramycine, sulfadiazine, folic acid and pyrimethamine. No interference with the assay was found.

In rare cases, interference due to extremely high titers of antibodies to streptavidin or ruthenium can occur. These effects are minimized by suitable test design.

For diagnostic purposes, the results should always be assessed in conjunction with the patient's medical history, clinical examination and other findings.

## Limits and ranges

### Measuring range

Reference measurement:

0.13-650 IU/mL (defined by the lower detection limit and the maximum of the master curve). Values below the lower detection limit are reported as < 0.13 IU/mL. Values above the measuring range are reported as > 650 IU/mL.

### Lower limits of measurement

*Lower detection limit of the test*

Lower detection limit: 0.13 IU/mL

The lower detection limit represents the lowest measurable analyte level that can be distinguished from zero. It is calculated as the value lying two standard deviations above that of the lowest standard (master calibrator, standard 1 + 2 SD, repeatability study, n = 21).

### Dilution

Samples with Toxo IgG concentrations > 500 IU/mL must be pre-diluted with Diluent Universal prior to testing with the Elecsys Toxo IgG Avidity assay. Please refer to the "Assay" section of this document for the recommended procedure.

### Specific performance data

Representative performance data on the analyzers are given below. Results obtained in individual laboratories may differ.

## Precision

Precision was determined using Elecsys reagents, samples and controls in a protocol executing single avidity measurements for each sample including the manual assay handling according to the assay workflow.

Repeatability (within-run precision): n = 21 single determinations (sample handling was performed by single operator).

Inter-Module precision: n = 8 single results per sample (two runs per module, 4 modules). The following results were obtained:

Elecsys 2010 and cobas e 411 analyzers			
	Repeatability		
Sample	Mean Avi%	SD Avi%	CV %
Human serum 1	49	2.1	4.3
Human serum 2	75	1.3	1.7
Human serum 3	93	0.6	0.6
PC <sup>b)</sup> Toxo IgG Avidity 1	42	3.0	7.3
PC Toxo IgG Avidity 2	86	0.9	1.0

b) PC = PreciControl

MODULAR ANALYTICS E170, cobas e 601 and cobas e 602 analyzers			
	Inter-Module precision		
Sample	Mean Avi%	SD Avi%	CV %
Human serum 1	42	2.2	5.2
Human serum 2	51	4.3	8.7
Human serum 3	56	1.5	2.7
Human serum 4	80	1.2	1.5
Human serum 5	79	0.8	1.0
Human serum 6	87	0.5	0.5
Human serum 7	92	0.5	0.5
Human serum 8	94	0.0	0.0
PC Toxo IgG Avidity 1	53	1.5	2.8
PC Toxo IgG Avidity 2	90	0.5	0.5

## Analytical specificity

232 potentially cross reacting samples were tested with the Elecsys Toxo IgG assay (equivalent to the Elecsys Toxo IgG Avidity formulation) and a comparison Toxo IgG assay comprising specimens:

- containing antibodies against HBV, HCV, HIV\*\*, CMV, EBV, HSV, VZV\*\*, Parvo B19, Rubella, Treponema pallidum, Malaria\*, Amebiasis, Chlamydia and Gonorrhoea
- containing autoantibodies (AMA, ANA)
- after vaccination against HBV and Influenza

An overall agreement of 97.8 % (221/226) was found in these specimens with the Elecsys Toxo IgG assay and the comparison test. 127 samples were found concordantly negative and 94 samples were found positive. 6 samples were found indeterminate either with the Elecsys Toxo IgG assay or the comparison test.

\* Malaria: 3 samples which were found discordant positive with the Elecsys Toxo IgG assay, revealed also a positive result by a direct agglutination assay.

\*\*VZV: 1 discordant positive sample; HIV: 1 discordant negative sample with the Elecsys Toxo IgG assay

## Clinical studies

Overall 455 single and sequential samples (collected and classified by reference laboratories) were investigated with Elecsys Toxo IgG Avidity assay and two commercially available comparison methods. The presumed onset of infection of investigated specimen samples was determined as accurately as possible based on diagnostic testing and if available, clinical indications. The following 3 sample groups were analyzed:

- 135 samples from pregnant women with a presumed onset of infection within less than 4 months (referred to as acute infection).

# Toxo IgG Avidity

IgG antibody avidity to *Toxoplasma gondii*



- 159 samples from pregnant women with a presumed onset of infection within more than 4, but less than 9 months (referred to as late acute infection).
- 161 samples from pregnant women with a presumed onset of infection later than 9 months ago (referred to as remote infection).

The distribution of samples tested within the indicated assays is given in the table below:

Clinical status	Avidity	Elecsys Toxo IgG Avidity assay	Comparison method A	Elecsys Toxo IgG Avidity assay	Comparison method B
		n = 239 samples; site 1		n = 216 samples; site 2	
Acute infection	Low	64	68	65	65
	Gray zone	4	0	2	2
	High	0	0	0	0
Late acute infection	Low	58	61	50	52
	Gray zone	30	19	8	5
	High	12	20	1	2
Remote infection	Low	9	4	31	27
	Gray zone	16	3	10	10
	High	46	64	49	53

**References**

- Montoya JG, Liesenfeld O. Toxoplasmosis. *Lancet* 2004;363:1965-1976.
- Luft BJ, Remington JS. Toxoplasmic encephalitis in AIDS. *Clin Infect Dis* 1992;15:211-222.
- Khalifa KES, Roth A, Roth B, et al. Value of PCR for Evaluating Occurrence of Parasitemia in Immunocompromised Patients with Cerebral and Extracerebral Toxoplasmosis. *J Clin Microbiol* 1994;32:2813-2819.
- Remington JS, McLeod R, Desmonts G. Toxoplasmosis. *Infectious Diseases of the Fetus and Newborn Infant*, 5th ed. W.B. Saunders: Philadelphia, 2001;205-346.
- Thulliez P. Maternal and fetal infection: in Toxoplasmosis (eds D.H.M. Joynton, T.G. Wreghitt) Cambridge University Press, 2001:193-213 ISBN 0521 44328 8.
- Wong SY, Remington JS. Toxoplasmosis in pregnancy. *Clin Infect Dis* 1994;18:853-862.
- Petersen E. Toxoplasmosis. *Semin Fetal Neonatal Med*, 2007;12(3):214-223.
- Flori P, Chene G, Varlet MN, et al. Toxoplasma gondii serology in pregnant woman: characteristics and pitfalls. *Ann Biol Clin (Paris)* 2009;67(2):125-133.
- Occupational Safety and Health Standards: bloodborne pathogens. (29 CFR Part 1910.1030). Fed. Register.
- Directive 2000/54/EC of the European Parliament and Council of 18 September 2000 on the protection of workers from risks related to exposure to biological agents at work.

For further information, please refer to the appropriate operator’s manual for the analyzer concerned, the respective application sheets, the product information and the Method Sheets of all necessary components (if available in your country).

A point (period/stop) is always used in this Method Sheet as the decimal separator to mark the border between the integral and the fractional parts of a decimal numeral. Separators for thousands are not used.

**Symbols**

Roche Diagnostics uses the following symbols and signs in addition to those listed in the ISO 15223-1 standard.

- CONTENT Contents of kit
- SYSTEM Analyzers/Instruments on which reagents can be used
- REAGENT Reagent

- CALIBRATOR Calibrator
- Volume after reconstitution or mixing
- GTIN Global Trade Item Number

COBAS, COBAS E, ELECSYS and PRECICONTROL are trademarks of Roche. INTRALIPID is a trademark of Fresenius Kabi AB.

All other product names and trademarks are the property of their respective owners. Additions, deletions or changes are indicated by a change bar in the margin.

© 2015, Roche Diagnostics



Roche Diagnostics GmbH, Sandhofer Strasse 116, D-68305 Mannheim  
www.roche.com

